Clinical Trial Update: Clinical Trial of AGB101 for Mild Cognitive Impairment [Phase 2]

View source ↗

Summary

Phase 2 trial of AGB101 for Mild Cognitive Impairment and prodromal Alzheimer's disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• AGB101

Snippet

Sponsor: AgeneBio | Conditions: Mild Cognitive Impairment, Prodromal Alzheimer's Disease | Phase 2 | Status: WITHDRAWN